We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

Download Mobile App





Celltrion’s COVID- 19 Antiviral Antibody Treatment Shows Improved Recovery Time in Pre-Clinical Study

By HospiMedica International staff writers
Posted on 02 Jun 2020
Print article
Image: Celltrion’s COVID- 19 Antiviral Antibody Treatment Shows Improved Recovery Time in Pre-Clinical Study (Photo courtesy of Celltrion Group)
Image: Celltrion’s COVID- 19 Antiviral Antibody Treatment Shows Improved Recovery Time in Pre-Clinical Study (Photo courtesy of Celltrion Group)
Celltrion Group (Incheon, South Korea) has announced positive pre-clinical results for its COVID-19 antiviral antibody treatment, with data demonstrating a 100-fold reduction in the viral load of SARS-CoV-2.

The treatment was also able to show improvement in lung lesions to a normal activity level in animal models. The announcement follows the identification of antibody candidates for an antiviral treatment which Celltrion completed in April.

The trial set out to assess the efficacy of two dosage amounts (low and high) for the antiviral antibody treatment. In comparison to the placebo-controlled group, the research team observed improved recovery in terms of clinical symptom scores such as runny nose, cough and body aches, after the first day of treatment. From the fifth day, significant clinical remission was observed.

Reverse transcriptase polymerase chain reaction (RT-PCR) measurement and cell culture-based viral diagnosis were used to analyze specimens from the upper respiratory tract (nasal discharge and nasal turbinate) and the lungs. The samples from the high-dose group saw the viral load reduce by 100-fold. Furthermore, lung biopsy showed that both dosage groups saw inflammation returning to normal lung tissue histopathology within six days as well as a shortened recovery time, whereas the placebo-controlled group experienced sustained levels of lung inflammation and complications.

“Celltrion is drawing on its expertise, innovation and previous experience in coronaviruses, such as efforts researching the efficacy of CT-P38, an investigational antibody to treat Middle East Respiratory Syndrome (MERS), as well as CT-P27, a multi-antibody drug for influenza which is being tested in a phase 2b study, to develop a safe and effective treatment for COVID-19,” said Ki-Sung Kwon, Head of R&D Unit at Celltrion. “Celltrion is leveraging its advanced technologies to lead efforts to develop a novel antiviral antibody treatment containing potent therapeutic antibodies that can neutralize the virus. Celltrion hopes to commence first-in-human clinical trials in July and has the capability to roll out mass production of the therapeutic antibody treatment once it is ready.”

Related Links:
Celltrion Group


Print article

Channels

Business

view channel
Illustration

Omnia Health Live Unites Global Healthcare Community Through New Virtual Experience

Omnia Health Live, a virtual healthcare event, has brought the global healthcare community together on a scale never seen before through a new experience delivered entirely online. The virtual healthcare... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.